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Abstract

Author Manuscript

Bone marrow microenvironment mediated downregulation of BCL6 is critical for maintaining cell
quiescence and modulating therapeutic response in B-cell acute lymphoblastic leukemia (ALL). In
the present study, we have performed a high throughput cell death assay using BCL6 knockdown
REH ALL cell line to screen a library of FDA-approved oncology drugs. In the process, we have
identified a microtubule inhibitor, cabazitaxel (CAB), and a RNA synthesis inhibitor, plicamycin
(PLI) as potential anti-leukemic agents. CAB and PLI inhibited cell proliferation in not only the
BCL6 knockdown REH cell line, but also six other ALL cell lines. Furthermore, combination of
CAB and PLI had a synergistic effect in inhibiting proliferation in a cytarabine-resistant (REH/
Ara-C) ALL cell line. Use of nanoparticles for delivery of CAB and PLI demonstrated that the
combination was very effective when tested in a co-culture model that mimics the in vivo bone
marrow microenvironment that typically supports ALL cell survival and migration into protective
niches. Furthermore, exposure to PLI inhibited SOX2 transcription and exposure to CAB inhibited
not only Mcl-1 expression but also chemotaxis in ALL cells. Taken together, our study
demonstrates the utility of concomitantly targeting different critical regulatory pathways to induce
cell death in drug resistant ALL cells.
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1.

Introduction

Author Manuscript

B-cell acute lymphoblastic leukemia (ALL) manifests itself as an accumulation of poorly
differentiated malignant lymphoid cells within the bone marrow (BM), resulting in the
disruption of normal hematopoiesis [1]. BM is also the most common site of disease relapse,
contributed by minimal residual disease (MRD), a major factor associated with poor
prognosis and mortality [2]. Unlike T-cell lymphoblastic leukemia, MRD in ALL has been
less completely studied and its etiology still remains to be more clearly delineated [3].
However, there is sufficient evidence that the maintenance of MRD is due, in part, to the
ability of the BM microenvironment to provide sanctuary to the ALL cells allowing
malignant cells to survive, even in the presence of chemotherapy [4,5]. Interestingly, MRD
cells became sensitive following release from their BM niche, emphasizing the crucial role
of the BM microenvironment in contributing to therapeutic resistance [6]. Within the BM
niche, in addition to often being non-responsive to chemotherapy, ALL cells have been
described as quiescent with ‘stem cell like’ characteristics [6–8]. Hence, in order to consider
strategies to eradicate MRD, the ability of ALL cells to migrate to the BM niche has to be
considered in addition to the quiescent and drug resistant phenotype acquired when resident
within the niche.

Author Manuscript
Author Manuscript

We previously developed an in vitro co-culture model of ALL cells with either primary
human-derived BM stromal cells or osteoblasts (components of the BM niche) [9]. From this
co-culture we characterized a drug resistant sub-population of leukemic cells referred to as
“phase dim” (PD), based on their lack of light refraction coincident with their migration
beneath adherent layers of stroma or osteoblasts. The PD tumor cells are used to model cells
that contribute to MRD in vivo based on phenotypic similarities [9]. Using this niche-based
co-culture model, we have reported that primary ALL samples, or ALL cells in co-culture
with the BM cellular components, have reduced BCL6 expression in the PD cell population
[10]. Furthermore, reduction in BCL6 resulted in disruption of cell cycle progression, with
cyclin D3-dependent accumulation of cells in the G0/G1 phase. The importance of BCL6 in
maintaining cell quiescence, drug resistance and the resulting MDR phenotype was further
validated in vivo by demonstrating significant event free survival in mice treated with a
combination of caffeine (stabilizer of BCL6) and cyatarabine (Ara-C) when compared to
mice treated with Ara-C alone [10]. BCL6 has also been shown to be a master regulator of
glycolysis by directly repressing the overall gene program of the glycolytic pathway [11].
Not surprisingly, we have shown that drug resistant PD ALL cells, characterized by reduced
expression of BCL6, demonstrate increased glycolysis coincident with upregulation of
several molecules that modulate the metabolic pathway, including hexokinase II [9,10].
Based on these observations we screened for drugs that induce death in leukemic cells with
diminished BCL6, with the intent to identify agents that could be tested for efficacy in
targeting MRD in ALL.
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In the present study, we have successfully screened a library of FDA-approved oncology
drugs in a BCL6 knockdown ALL cell line and identified cabazitaxel (CAB) and plicamycin
(PLI) as potential candidates that could target and eliminate drug resistant leukemic cells.
We further validated the anti-leukemic activity of CAB and PLI in six ALL cell lines and
demonstrated that part of the anti-leukemic activity was attributed to cell cycle arrest.
Furthermore, to show activity in low expressing BCL6 cells, we demonstrated synergism of
the CAB/PLI combination in a cytarabine resistant REH cell line (REH/Ara-C) and our coculture model. Collectively our observations suggest this combination therapy, with
inhibition of chemotaxis and downstream modulation of SOX2 and Mcl-1, warrants further
evaluation in settings that are refractory to traditional chemotherapy.

2.
Author Manuscript

2.1.

Materials and methods
Cell culture and chemicals

Author Manuscript

The development of doxycycline-inducible REH BCL6 knockdown cells and its comparative
REH scrambled stable cells has been previously published [10]. SUPB15 (ATCC
#CRL-1929) and JM1 (ATCC #CRL-10423) were purchased and maintained in RPMI 1640
containing 10% FBS, 0.05 mM β-mercapto-ethanol and 1X streptomycin/penicillin
antibiotics. REH (ATCC #CRL-8286), NALM1 (ATCC #CRL-1567), NALM6 (DSMZ ACC
#128), BV173 (DSMZ ACC#20), RS4 (ATCC #CRL-1873) and SD1 (DSMZ ACC#366)
were purchased and maintained in RPMI 1640 containing 10% FBS and 1X streptomycin/
penicillin antibiotics. Human osteoblasts (HOB) was purchased from PromoCell (Cat No:
C-12720, Hiedelberg, Germany) and cultured according to the vendor’s recommendations.
All the ALL cell lines were authenticated by short tandem repeat (STR) analysis (University
of Arizona Genetic Core, Tuscon, Az) and maintained in 6% CO2 in normoxia at 37 °C.
Primary immune cells CD3+ T cells, CD19+ B cells, peripheral blood mono-nuclear cells
(PBMC) and bone marrow mononuclear cells (BMMC) were all purchased from
ALLCELLS and maintained in Lymphocyte growth medium −3 (Lonza, Cat No: CC-3211)
containing 10% FBS and 1X streptomycin/penicillin antibiotics. De-identified primary
human ALL cells were obtained from the West Virginia University Health Sciences Center
and West Virginia University Cancer Institute Biospecimen Processing Core. CAB and PLI
were purchased from Fisher Scientific (Cat No: 501014444 and 50488911, respectively) and
stored at −80 °C as a 10 mM stock.
2.2.

High throughput screening assay

Author Manuscript

FDA-approved oncology drug set VII was obtained from NCI/NIH in 96 well plate format
with each well containing 20 μl of 10 mM drug stock. REH BCL6 knockdown and
scrambled cells were treated with 1 μg/ml of doxycycline for 24 h (to induce shRNA
expression) and then cultured in a 96 wells plate at 50,000 cells per well. Drugs were added
in triplicate at log concentrations with the lowest concentration of0.1 μM and the highest
concentration of 100 μM. The cells were incubated for 72 h in a humidified atmosphere
under 5% CO2 at 37 °C following which the cell viability and the IC50 was measured and
analyzed as described below.
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Cell viability assay
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ALL cells were grown in 96-well plates at 50,000 cells per well and treated with CAB or
PLI at indicated concentrations. Cell viability was measured 72 h post-treatment using a cell
counting kit according to the manufacturer’s instructions (Dojindo Molecular Technologies
Inc., Cat No: CK04). Briefly, 10 μl of the assay reagent was added to each well and
incubated for 2 h at 37 °C in normoxia, after which the plates were read on a BioTek
Cynergy 5 plate reader at 450 nm absorbance. Untreated cells were used as controls. IC50
and combination index (CI) was analyzed using compusyn (www.combosyn.com).
2.4.

Cell cycle analysis

Author Manuscript

ALL cells at 106 cells/ml were treated with either 3 nM of CAB or 15 nM of PLI for 24 h.
Post-treatment the cells were washed with phosphate buffered saline (PBS) and fixed using
70% ethanol for 30 min at 4 °C. After incubation, the cells were washed with PBS and resuspended in a staining buffer containing 50 μg/ml of propidium iodide (PI) and 100 μg/ml
of RNase A. Cells were incubated for 30 min in the staining buffer, followed by wash and
analysis of the DNA content using flow cytometry.
2.5.

Long-term co-culture and isolation of leukemic cell population

Author Manuscript

Long-term co-culture conditions have been previously described [9]. Briefly, 1 million REH
cells were seeded on 85% confluent HOB layer and maintained in 5% O2. The co-culture
was fed every 4 days and on the 12th day in culture, REH cells were isolated for western
blotting. The leukemic cell population that were in suspension and not interacting with the
osteoblasts were removed and spun down and designated as suspended cells (S). The REH
cells which are buried under the HOB were separated by size exclusion with G10 sephadex
after vigorous washing. These buried REH cells were designated as phase dim cells (PD)
and have been previously described to be representative of MRD [10,12].
2.6.

Nanoparticle drug delivery system
The nanoparticles were prepared as described earlier [13]. Briefly, 2 mg of CAB or PLI were
dissolved in 500 microliters of acetone containing 20 mg PEG-PLGA-COOH and added
dropwise into a constantly stirring 25 mM of MES (pH 5). The organic solvent was allowed
to evaporate in a fume hood and the nanoparticles (NP) were activated for 1 h using a 25
mM solution of MES containing 20 mg NHS and 20 mg EDC (pH 5). The quality of the
resultant NP was analyzed using NanoSight NS300 (Malvern Instruments Ltd, UK).

2.7.

Cell death analysis

Author Manuscript

12-day co-culture experiments were carried out as described above in a 24-well plate. On
day 10, the cells were treated with either CAB, PLI, combination of CAB and PLI (C + P) or
Ara-C. After 48 h (day 12), the live ALL cells were counted using trypan blue dye exclusion
method and the % viability was calculated.
2.8.

Hemosphere assay
SD1 cells were plated at 100,000 cells/well and allowed to form spheroids in a 96 well plate.
The formation of spheroids was visualized and confirmed using light microscope and then
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treated with 15 nM of PLI for 72 h. Post-treatment, the drug effects on the spheroids were
captured using a Leica camera attached to a Leica DMIL LED microscope.
2.9.

Western blots
REH cell pellet was re-suspended in RIPA buffer and vortexed for 15 min followed by
centrifugation at 4 °C at 20,000 g to collect the protein extract. Protein content was
determined by using BCA method and resolved on SDS-PAGE gels and transferred to
nitrocellulose membranes. Membranes were blocked (TBS with 5% Milk and 0.05%
Tween-20) and probed with primary antibody and horseradish peroxidase conjugated
secondary antibody. Signals were visualized with chemiluminescence reagents using an
imager. Antibodies for BCL6, CDKN1B, Mcl-1, Bcl-2 and Bcl-xL were purchased from
Cell Signaling (Cat No: 5650, 3688, 9426, 2872 and 2764 respectively) and GAPDH
antibody was purchased from Fisher Scientific (Cat No: 10R-G109a).

Author Manuscript

2.10.

Chemotaxis assay
Transwell with 5 μm pore size (Corning, Cat No: 3421) were used for the assay and the
chemoattractant was either SDF-1 [100 ng/ml] or adherent HOB (placed in the bottom well
of the transwell). REH cells were treated with 2 nM CAB for 1 h and then plated on the
transwell inserts and allowed to migrate towards the bottom for 4 h. The migrated cells were
counted using a flow cytometer.

2.11.

Statistical analysis

Author Manuscript

All the experiments were carried out in triplicates in three individual experiments unless
otherwise stated. All the data was represented as Mean ± SEM and p < 0.05 was considered
as statistically significant. Statistical significance between groups was determined using oneway ANOVA followed by a post-hoc Tukey’s test.

3.

Result

3.1. High throughput screening identifies cabazitaxel and plicamycin as potential antileukemic agents

Author Manuscript

A total of 129 FDA-approved oncology drugs were screened for its selective anti-leukemic
activity in REH cells with knockdown BCL6 compared to REH cells with expression of
BCL6 comparable to parental REH cells. The inducible knockdown of BCL6 after
doxycycline treatment was confirmed by western blotting (Suppl. 1). As seen in Fig. 1, 66
drugs from the library had IC50 values less than 10 μM and out of this, cabazitaxel (CAB)
(red circle) and plicamycin (PLI) (blue circle) showed increased sensitivity in BCL6
knockdown cells compared to the cells expressing parental levels of BCL6. Importantly, a
more thorough concentration-response analysis demonstrated that CAB had an IC50 value of
1 nM in BCL6 knockdown REH cells compared to 3.25 nM in the parental REH cell line
and at the same time PLI had an IC50 value of8.95 nM in BCL6 knockdown cells compared
to 21.9 nM in the parental cells (Fig. 2). To confirm that the anti-leukemic activity of CAB
and PLI extended to other ALL cell lines, irrespective of their molecular bio-genesis, we
utilized six different ALL cell lines (BV173, JM1, NALM1, NALM6, RS4 and SUPB15).
As seen in Fig. 3A & C, CAB and PLI decreased cell viability in a concentration dependent
Leuk Res. Author manuscript; available in PMC 2019 September 01.
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manner in all the cell lines tested. The efficacy of the drugs in inhibiting viability exhibited a
very tight spectrum with the CAB being most effective in BV173 cells at a low
concentration (IC50 = 1.8 nM) with higher concentrations required in NALM1 (IC50 = 4.94
nM). PLI was most effective in NALM6 (IC50 = 15.72 nM) and the RS4 cell line being
notably resistant (IC50 = 37.26 nM) (Fig. 3B & D).
3.2. Combination therapy of cabazitaxel and plicamycin shows synergism in drug
resistant ALL cell line

Author Manuscript
Author Manuscript

Since, our previous experiment showed a different profile of sensitivity of CAB and PLI in
the ALL cell lines, we decided to test the efficacy of the combination in (i) Ara-C resistant
REH cell line, REH/Ara-C (Suppl. 2), (ii) primary ALL samples and (iii) primary normal
immune cells. As seen in Fig. 4A, at the doses tested, while CAB and PLI were unable to
inhibit proliferation when treated alone, the combination of CAB and PLI synergistically
inhibited proliferation as assessed by combination index of less than 1 at effective
concentrations of the combination that decreased viability by 75, 90 and 95% (Fig. 4A).
Interestingly, BCL6 expression in the REH/Ara-C cell lines where lower compared to its
parental REH cell lines (Fig. 4B). Next, we tested the activity of the combination in two
newly diagnosed and one relapsed primary ALL patient samples. As seen in Fig. 4C, the
combination of CAB and PLI demonstrated activity at a single combination dose in all the
three primary cell lines. However, the extent of its activity varied, with the combination
being most effective in the relapsed patient ALL cells (40% cell viability). Furthermore, the
activity of the combination was selective for leukemic cells, as the combination did not
significantly change the viability of normal immune cells like CD3+ T cells, CD19+ B cells
or normal peripheral mononuclear cells and bone marrow mononuclear cells (Fig. 4D). To
further elucidate the activity of CAB, PLI and the combination in leukemic cells, we
performed a cell cycle analysis. As seen in Fig. 4E & F, while CAB had no effect on the cell
cycle, PLI significantly increased the number of cells in G0 that was inversely proportional
to a significant decrease of cells in S. This effect of the PLI was maintained in the
combination in both REH and TOM1 cell lines and correlated with an increase in the
expression of CDKN1B in these cells after treatment (Suppl. 3).
3.3. Combination therapy of nanoparticle-encapsulated cabazitaxel and plicamycin
targets the drug resistant ALL cell population in co-culture

Author Manuscript

We had previously reported the utility of our co-culture model in studying the drug resistant
cell population called PD cells that mimic the properties of MRD found in the BM
microenvironment [9]. In the present study, we first tested the uptake of rhodamine-loaded
nanoparticles (NP) in our co-culture model. As seen in Supplementary data 4, the NP
preferentially were taken up by leukemic cells when compared to the HOB cells. Next, we
tested the treatment of nanoparticle encapsulated CAB, PLI or their combination in the coculture of ALL cells (either REH or SUPB15) with HOB. After 48 h of treatment, we
observed that the single treatment of CAB or PLI were similar in activity in reducing the live
cell population of the cells in suspension (S) and the drug resistant phase dim (PD) cells in
both REH and SUPB15 co-cultures. Interestingly, the combination of the CAB and PLI
reduced the live cell population statistically significantly in the PD cell population of both
REH and SUPB15 (Fig. 5A & C). Similarly, the combination treatment reduced the viability
Leuk Res. Author manuscript; available in PMC 2019 September 01.
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of the REH PD cells to 22.2% and SUPB15 PD cells to 27.28% compared to the untreated
PD cells (Fig. 5B & D).
3.4.

Plicamycin shows anti-leukemic activity in a hemosphere assay

Author Manuscript

To determine the relevance of SOX2 expression in primary ALL samples, we performed
real-time RT-PCR and determined that SOX2 was overexpressed three ALL patient samples
compared to REH cells (Suppl. 5A). In order to mimic SOX2 overexpression in leukemic
cells, we performed a hemosphere assay and showed up-regulation of the stem cell factor,
SOX2 (Suppl. 5B). To investigate, if PLI manifests its anti-leukemic activity by inhibition of
SOX2 transcription, we tested the activity of PLI in a hemosphere assay. After confirmation
of hemosphere formation, the same were treated with 15 nM of the PLI. After 72 h of
treatment, quantitation of the spheres using light microscopy showed that the PLI was very
efficient in disrupting pre-formed SD1 hemosphers (13 spheroids in PLI treated vs. 31
spheroids in control) (Fig. 6A).
3.5.

Cabazitaxel inhibits Mcl-1 expression and chemotaxis in ALL

Author Manuscript

Anti-apoptotic protein Mcl-1 expression and chemotaxis have both been shown to be
regulated by microtubules [14,15]. To determine the relevance of Mcl-1 expression in
primary ALL samples, we performed western blotting analysis and determined that it was
expressed in three primary ALL patient samples (Suppl. 6A). Interestingly, Mcl-1 was
overexpressed in the drug resistant PD cell population in our co-culture (Suppl. 6B). Next
we determined the effect of CAB on Mcl-1 expression in ALL cells in co-culture (S & PD)
compared to ALL cells grown in media (M). As seen in Fig. 6B. CAB (3 nM) selectively
decreased the Mcl-1 in PD cells compared to cells in suspension (S) in the co-culture or cells
grown in media (M). Surprisingly, this decrease in Mcl-1 was accompanied by an increase in
Bcl-xL expression while Bcl-2 expression remained relatively unchanged. Finally, we
performed a chemotaxis assay and demonstrated that pre-treatment with 2 nM of CAB
significantly reduced migration of REH towards the chemoattractant (both SDF-1 and
HOB).

4.

Discussion

Author Manuscript

Eradication of MRD in leukemic patients is a major challenge impeding complete ablation
of the disease. Factors affecting progress include; (i) inability of the standard of care to
specifically target and induce death of refractory cells that comprise MRD within the BM
and(ii) high cost of drug discovery coupled with a high rate of attrition of successful drugs
that make it to the clinic. In the present study, we have used our model of MRD to screen for
already FDA-approved oncology drugs. Identified hits, in our screening, were then
compared to reported studies that used ex vivo and in vivo models of ALL to test for drug
efficacy [16,17]. Using this approach, we have identified CAB and PLI as potential
combination therapy for use in targeting MRD. Since, the ADME profile and mechanism of
action of both these drugs has already been established [18–21], it allows for accelerated
progression of these drugs through the pre-clinical stages of development for use in ALL
patients.
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PLI is an aureolic acid-type polyketide produced by Streptomyces strain that has been used
clinically in the treatment of testicular cancer and Ewing sarcoma [22–24]. The main mode
of anti-tumor activity of PLI was found to be inhibition of RNA synthesis and specifically its
activity on targeting SOX2+ spheroids has been very well characterized [25–27]. In the
present study, we utilized a hemoshpere assay that enriches for SOX2+ ALL cells to confirm
PLI’s potential to influence tumor cells in a SOX2-associated manner.

Author Manuscript

CAB is semisynthetic taxane specifically developed to overcome taxane resistance and it
acts through microtubule inhibition causing apoptosis by microtubule stabilization [28].
CAB is used in the clinic for the treatment of prostate cancer and breast cancer [29–31]. In
the present study we observed that CAB mediated death in drug resistant ALL cells
correlated with its ability to inhibit Mcl-1 and chemotaxis. Mcl-1 overexpression has been
shown to be critical for ALL survival [32–34], and microtubule disruption has been shown to
induce Mcl-1 degradation [35]. One of the interesting finding in our study was the
compensatory overexpression of Bcl-xL and it would be relevant to study the combination of
CAB with a specific Bcl-xL inhibitor in future studies. At the same time, soluble factor
gradients driving chemotaxis play an important role in leukemic niche development [36,37].
Importantly, leukemia propagating cells have been shown to rebuild their niche in response
to chemotherapy [38]. Taken together, our data suggests that in addition to microtubule
inhibition, degradation of Mcl-1 and chemotaxis, all together encompasses the full spectrum
of CAB’s anti-leukemic activity.

Author Manuscript

CAB and PLI have a well-characterized toxicity profile reported from multiple trials [39,40].
Neutropenia is the dose limiting toxicity during CAB therapy [29,30] with hemorrhagic and
hepatotoxicity associated with PLI [41,42]. NPs are shown to reduce systemic toxicity and
also demonstrate preferential uptake by cancer cells [43,44]. With these toxicities in mind
we incorporated a NP formulation for drug delivery into our model to establish the potential
for targeted drug delivery in future studies, based on the ease of conjugating antibodies on
the surface of these PEG-PLGA derived NP [45,46]. This is not intended to suggest
targeting in an overly simplified manner, but rather that the approach has viability moving
forward as one mechanism to reduce toxicity.

5.

Conclusion

Author Manuscript

In summary, we have shown the anti-leukemic activity of CAB and PLI in; (i) ALL cell lines
driven by different oncogenic signals, (ii) an ALL cell line with acquired drug resistance
(REH/Ara-C) and primary ALL patient samples, and (iii) ALL cells with de novo drug
resistance (co-culture model). Taken together, the CAB and PLI combination comprises a
new therapeutic strategy for treating relapsed leukemic disease that is refractory to the
present standard of care.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ALL

acute lymphoblastic leukemia

BM

bone marrow

MRD

minimal residual disease

CAB

cabazitaxel
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plicamycin

NP

nanoparticles

PD

phase dim
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Fig. 1.

High-throughput screening analysis in BCL6 knockdown cells. REH cell lines with
doxycycline-inducible BCL6 shRNA (BCL6-Knock down) or scrambled shRNA (BCL6Wild type) were treated with 1 μg/ml of doxycycline for 24 h. Following treatment, the cells
were washed and plated in a 96 well plate at 50,000 cells/well and treated with 129 FDAapproved oncology drugs in a 4-point log concentration. The cell viability at the end of 72 h
was measured as described in the methods section. IC50 values were measured and plotted.
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Concentration-dependent curve for cabazitaxel and plicamycin. REH cell lines with
doxycycline-inducible BCL6 shRNA (BCL6-Knock down) or REH parental cells were
treated with 1 μg/ml of doxycycline for 24 h. Following treatment, the cells were washed
and treated with a 9-point concentration of either cabazitaxel or plicamycin (A & C). Cell
viability was measured at the end of 72 h and the resulting concentration-curves were used
to calculate the IC50 values using Compusyn (B & D). The data was represented as Mean ±
SEM of a study performed in triplicate at least three independent times. *P < 0.05, when
compared to BCL6-Wild type.
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Anti-leukemic activity of cabazitaxel and plicamycin. ALL cell lines were plated at 50,000
cells/well in a 96 well cell culture plate and treated with indicated concentrations of either
cabazitaxel (A) or plicamycin (C). 72 h post-treatment the cell viability was measured as
described in methods. IC50 values were calculated from the concentration curves for
cabazitaxel (B) and plicamycin (D) using the compusyn software. The data was represented
as Mean ± SEM of a study performed in triplicates at least three independent times.
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Fig. 4.
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Combination therapy of cabazitaxel and plicamycin in leukemic cells. (A) REH/Ara-C cells
were plated at 50,000 cells/well in a 96 well cell culture plate and treated with indicated
concentrations of either cabazitaxel (CAB), plicamycin (PLI) or combination of cabazitaxel
and plicamycin (CAB + PLI). 72 h post-treatment the cell viability was measured as
described in methods. Combination index (CI) values were calculated from the
concentration curves for the combination using the compusyn software (inset table). (B)
REH and REH/ARA-C cells were plated at 106 cells/ml and after 48 h processed for western
blotting as described in the method section. (C) Primary ALL cells were plated at 50,000
cells/well in a 96 well cell culture plate and treated with combination of cabazitaxel and
plicamycin (CAB + PLI). 72 h post-treatment the cell viability was measured as described in
methods. (D) Normal primary immune cells were pated at 106 cells/ml in a 24 well plate and
then treated with combination of CAB + PLI for 24 h. The cells were then processed for
flow cytometry using a Live/Dead stain following the manufacturer’s instructions
(ThermoFisher Scientific, Cat No: L34963). REH (E) and TOM1 (F) cells were treated with
either cabazitaxel (CAB), plicamycin (PLI) or combination of cabazitaxel and plicamycin
(CAB + PLI). 24 h post-treatment the cell cycle analysis was performed as described in
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methods. The data was represented as Mean ± SEM of a study performed in triplicate at
least three independent times. (*P < 0.05, when compared to V.C treated group).
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Anti-leukemic activity of the combination therapy of cabazitaxel and plicamycin in coculture. REH (A & B) and SUPB15 (C & D) were grown in a co-culture with osteoblast
(HOB) in a 24 well plate for 12 days. On day 10 in co-culture, the cells were treated with
either 3 nM of cabazitaxel (CAB) or 15 nM of Plicamycin (PLI) or their combination (C +
P). All drugs were delivered in a nanoparticle encapsulated formulation. At the end of
treatment, the live cells were counted, using trypan blue dye exclusion method, in
suspension (S) and phase dim (PD) population when in co-culture using REH (A) and
SUPB15 (C). The total cells and the live cell population was used to calculate the % viability
in REH (B) and SUPB15 (D). The data is presented as Mean ± SEM and is a representative
of a study performed in triplicate and conducted three independent times. *P < 0.05, when
compared to all treatment groups.
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Fig. 6.
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Mechanism of action of plicamycin and cabazitaxel in leukemic cells. (A) SD1 cells were
plated at 100,000 cells/well and the spheroids were visualized using light microscope after 4
days in culture. After spheroid formation confirmation the cells were treated with 15 nM of
plicamycin (PLI) or vehicle(V.C). After 72 h of treatment, the resulting hemosphere images
were captured and counted. (B) REH cells were maintained in media alone or in co-culture
with oseteoblast for 12 days. The cells were treated with cabazitaxel (3 nM) for 2 days and
at the end of treatment, the different sub-populations were isolated and subjected to western
blotting. GAPDH was used as loading control and the blots are representative of an
experiment performed two independent times. (C) REH cells were plated on the insert and
allowed to migrate towards the bottom well containing no chemoattractant (media), 100
ng/ml of SDF-1 or osteoblast (HOB). The number of migrated cells were enumerated using
flow cytometry after 4 h. The data is presented as Mean ± SEM and is a representative of a
study performed in triplicates and conducted three independent times. *P < 0.05, when
compared to all untreated cells.
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